Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2024-05-13 00:00:00 ET · period of report 2024-05-10 · accession 0001104659-24-060263 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-13 | 2024-05-10 | NVCT | BENTSUR RON | COB, CEO, Dir, 10% | P - Purchase | $6.40 | +2,000 | 3.24M | +0.1% | +$12.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-10 | P | A | 2,000 | $6.40 | 3,244,484 | D | — | — | (F1) Reflects the weighted average purchase price. The range of prices for the shares purchased was $6.31 to $6.44. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price (F2) Includes 426,759 shares of restricted stock. |